SG Americas Securities
MRNA icon

SG Americas Securities’s Moderna MRNA Stock Holding History

SG Americas Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1M Sell
229,220
-21,648
-9% -$1.12M 0.01% 673
2026
Q1 		$12.7M Sell
250,868
-27,930
-10% -$1.3M 0.01% 704
2025
Q4 		$8.22M Sell
278,798
-10,044
-3% -$273K 0.01% 858
2025
Q3 		$7.46M Sell
288,842
-270,287
-48% -$7.54M 0.03% 393
2025
Q2 		$15.4M Buy
559,129
+487,734
+683% +$12.8M 0.06% 227
2025
Q1 		$2.02M Sell
71,395
-38,366
-35% -$1.36M 0.01% 787
2024
Q4 		$4.56M Buy
109,761
+56,982
+108% +$2.72M 0.02% 369
2024
Q3 		$3.53M Sell
52,779
-59,706
-53% -$5.48M 0.01% 517
2024
Q2 		$13.4M Buy
112,485
+33,175
+42% +$4.2M 0.08% 262
2024
Q1 		$8.45M Buy
79,310
+38,809
+96% +$3.91M 0.04% 409
2023
Q4 		$4.03M Sell
40,501
-172,166
-81% -$14.5M 0.04% 402
2023
Q3 		$22M Buy
212,667
+138,857
+188% +$15.5M 0.25% 62
2023
Q2 		$8.97M Buy
73,810
+49,335
+202% +$6.58M 0.07% 195
2023
Q1 		$3.76M Sell
24,475
-28,430
-54% -$4.69M 0.04% 373
2022
Q4 		$9.5M Buy
52,905
+36,526
+223% +$5.97M 0.12% 149
2022
Q3 		$1.94M Sell
16,379
-13,251
-45% -$2.01M 0.02% 595
2022
Q2 		$4.23M Sell
29,630
-170,320
-85% -$24.3M 0.05% 355
2022
Q1 		$34.4M Buy
199,950
+160,555
+408% +$27M 0.25% 62
2021
Q4 		$10M Buy
39,395
+16,063
+69% +$4.7M 0.05% 270
2021
Q3 		$8.98M Buy
23,332
+2,951
+14% +$1.09M 0.04% 304
2021
Q2 		$4.79M Sell
20,381
-125,249
-86% -$22.4M 0.02% 608
2021
Q1 		$19.1M Buy
145,630
+121,046
+492% +$17.5M 0.1% 178
2020
Q4 		$2.57M Sell
24,584
-65,047
-73% -$6.58M 0.01% 924
2020
Q3 		$6.34M Buy
89,631
+81,133
+955% +$5.66M 0.04% 276
2020
Q2 		$546K Buy
+8,498
New +$465K ﹤0.01% 2021

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

SG Americas Securities's MRNA Position: Q2 2026 in Review

SG Americas Securities reduced its Moderna (MRNA) stake by 8.6% in Q2 2026, selling an estimated $1.12M and leaving 229,220 shares worth $16.1M. The position accounts for 0.01% of the portfolio, ranked #673.

SG Americas Securities first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $34.4M in Q1 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • SG Americas Securities held 229,220 shares of Moderna worth $16.1M as of Q2 2026.
  • SG Americas Securities sold 21,648 Moderna shares in Q2 2026, an estimated $1.12M.
  • Moderna made up 0.01% of SG Americas Securities's portfolio in Q2 2026, its #673 holding.
  • SG Americas Securities first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • SG Americas Securities's Moderna position peaked at $34.4M in Q1 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.